OBJECTIVE: To review the literature describing female orgasmic disorder and impaired sexual desire disorder by selective serotonin reuptake inhibitors (SSRIs) and their treatment, including the use of sildenafil. STUDY DESIGN: Literature reviews of all available published articles on this topic from 1989 to 1996 were done. This paper also includes a sample case of a 38-year old woman who suffers from fluoxetine-induced arousal and orgasmic disturbance. RESULTS: Treatment approaches include the use of "antidotes," such as cyproheptadine, yohimbine, amantadine, granisetron and ginkgo biloba. This article also reports a case of successful female use of sildenafil, which was released by the Food and Drug Administration in March 1998 for erectile dysfunction in men. CONCLUSION: Sildenafil is beneficial in reversing female sexual dysfunction induced by SSRIs. This paper also discusses sildenafil's action in the background of nitric oxide and cyclic guaninosine monophosphate in penile/clitoral erection.
OBJECTIVE: To review the literature describing female orgasmic disorder and impaired sexual desire disorder by selective serotonin reuptake inhibitors (SSRIs) and their treatment, including the use of sildenafil. STUDY DESIGN: Literature reviews of all available published articles on this topic from 1989 to 1996 were done. This paper also includes a sample case of a 38-year old woman who suffers from fluoxetine-induced arousal and orgasmic disturbance. RESULTS: Treatment approaches include the use of "antidotes," such as cyproheptadine, yohimbine, amantadine, granisetron and ginkgo biloba. This article also reports a case of successful female use of sildenafil, which was released by the Food and Drug Administration in March 1998 for erectile dysfunction in men. CONCLUSION:Sildenafil is beneficial in reversing female sexual dysfunction induced by SSRIs. This paper also discusses sildenafil's action in the background of nitric oxide and cyclic guaninosine monophosphate in penile/clitoral erection.
Authors: Stephen L Archer; Ferrante S Gragasin; Linda Webster; Derek Bochinski; Evangelos D Michelakis Journal: Drugs Aging Date: 2005 Impact factor: 3.923